RECRUITING

Pancreatic Cancer Detection Consortium

Talk to us

Conditions

Pancreatic CancerPancreatic CarcinomaPancreatic AdenocarcinomaPancreatic Ductal AdenocarcinomaPancreatic NeoplasmsPancreatic Cancer Stage IPancreatic Cancer StagePancreatic Cancer ResectablePancreatic Cancer Stage 0Pancreatic Cancer Stage IIPancreatic Cancer Stage IIIPancreatic Cancer, AdultPancreatic Cancer Non-resectableMicro RNAExosomeCell freeEarly detectionScreening

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

Official Title

Early Detection of Pancreatic Cancer: Prospective Study

Quick Facts

Study Start:2023-03-15
Study Completion:2025-11-21
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06388967

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition)
  2. * Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.
  3. * Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls)
  1. * Lack of written informed consent.

Contacts and Locations

Study Contact

Ajay Goel, PhD
CONTACT
6262183452
AJGOEL@COH.ORG

Principal Investigator

Ajay Goel, PhD
PRINCIPAL_INVESTIGATOR
City of Hope Medical Center

Study Locations (Sites)

Translational Genomics Research Institute
Phoenix, Arizona, 85004
United States
Honorhealth
Scottsdale, Arizona, 85258
United States
City of Hope Medical Center
Monrovia, California, 91016
United States
Hoag Center
Newport Beach, California, 92663
United States
OSF HealthCare
Peoria, Illinois, 61637
United States
Ochsner Medical Center
Jefferson, Louisiana, 70121
United States
Atlantic Health System
Morristown, New Jersey, 07960
United States
Piedmont Medical Center
Rock Hill, South Carolina, 29732
United States
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
United States

Collaborators and Investigators

Sponsor: City of Hope Medical Center

  • Ajay Goel, PhD, PRINCIPAL_INVESTIGATOR, City of Hope Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-03-15
Study Completion Date2025-11-21

Study Record Updates

Study Start Date2023-03-15
Study Completion Date2025-11-21

Terms related to this study

Keywords Provided by Researchers

  • Micro RNA
  • Exosome
  • Cell free
  • Early detection
  • Screening

Additional Relevant MeSH Terms

  • Pancreatic Cancer
  • Pancreatic Carcinoma
  • Pancreatic Adenocarcinoma
  • Pancreatic Ductal Adenocarcinoma
  • Pancreatic Neoplasms
  • Pancreatic Cancer Stage I
  • Pancreatic Cancer Stage
  • Pancreatic Cancer Resectable
  • Pancreatic Cancer Stage 0
  • Pancreatic Cancer Stage II
  • Pancreatic Cancer Stage III
  • Pancreatic Cancer, Adult
  • Pancreatic Cancer Non-resectable